FindTrial
Sign In

Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort

Effect of Glycopyrrolate and Atropine as Adjuncts to Reversal of Non-Depolarizing Neuromuscular Blocking Agents on Postoperative Catheter-Related Bladder Discomfort

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02228473
Enrollment
76
Registered
2014-08-29
Start date
2014-09-30
Completion date
2015-03-31
Last updated
2014-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Catheter Site Discomfort, Complications, Urinary Bladder Neoplasms

Brief summary

We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.

Detailed description

The mechanism of catheter-related bladder discomfort is thought to be related to the muscarinic receptor. The adjuncts to reversal agents such as glycopyrrolate and atropine are known to block the muscarinic receptor in different ways. We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.

Interventions

DRUGGlycopyrrolate

Glycopyrrolate will be administered.

DRUGAtropine

Atropine will be administered.

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for transurethral bladder excision under general anesthesia * ASA I-III

Exclusion criteria

* Foley catheter less than 18 Fr. * Patients with obstruction of urinary tract * Patients with neurogenic bladder * Patients with severe obesity * Patients with neurologic disorder * Patients with chronic pain * Patients with allergic history to atropine or glycopyrrolate

Design outcomes

Primary

MeasureTime frameDescription
Catheter-related bladder discomfort1 hour postoperativelyCatheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe).

Secondary

MeasureTime frameDescription
Catheter-related bladder discomfort0, 6 and 24 hour postoperativelyCatheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe).
Hemodynamic parameters0, 1, 5, 10 minute postoperativelyMean blood pressure and heart rate will be measured at 0, 1, 5, 10 minute postoperatively. Measurement at 10 minute means Mean blood pressure and heart rate at the admission of post-anesthetic care unit.
Nausea0, 1, 6 and 24 hour postoperativelyNausea will be measured at 0, 1, 6 and 24 hour postoperatively.
Vomiting0, 1, 6 and 24 hour postoperativelyVomiting will be measured at 0, 1, 6 and 24 hour postoperatively.
Dry mouth0, 1, 6 and 24 hour postoperativelyDry mouth will be measured at 0, 1, 6 and 24 hour postoperatively.
Blurred vision0, 1, 6 and 24 hour postoperativelyBlurred vision will be measured at 0, 1, 6 and 24 hour postoperatively.
Dizziness0, 1, 6 and 24 hour postoperativelyDizziness will be measured at 0, 1, 6 and 24 hour postoperatively.
Analgesics0, 1, 6 and 24 hour postoperativelyThe amount of analgesics will be measured at 0, 1, 6 and 24 hour postoperatively.
Flushing0, 1, 6 and 24 hour postoperativelyFlushing will be measured at 0, 1, 6 and 24 hour postoperatively.

Countries

South Korea

Contacts

Primary ContactHyun-Chang Kim, MD
onidori1979@gmail.com82-10-2886-2876

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026